Patrick J. Geraghty, MD
- Vascular Surgery
- Varicose Veins
- English
Appointments
Sees Patients For
Endovascular (minimally invasive) treatment of aortic aneurysms, aortoiliac occlusive disease, renovascular disease, carotid artery stenosis, lower extremity vascular disease, varicose veins, open surgical treatment for vascular diseases and hemodialysis access
Hospital Affiliations
- Barnes-Jewish Hospital
- Barnes-Jewish St. Peters Hospital
- Shriners Hospital for Children - St. Louis
Locations
- Center for Advanced Medicine Heart & Vascular Center4921 Parkview PlaceSt. Louis, MO 63110Suite: AFloor: 8Fax: 888-840-6225 Appointments:
- Barnes-Jewish St. Peters Hospital10 Hospital DriveSt. Peters, MO 63376Suite: Professional Office Building 2, Suite 201Fax: 888-840-6225 Appointments:
- Barnes-Jewish West County Hospital12634 Olive BoulevardSt. Louis, MO 63141Fax: 888-840-6225 Appointments:
- Center for Advanced Medicine – South County5201 Midamerica PlazaSt. Louis, MO 63129Suite: 2300Fax: 888-840-6225 Appointments:
Experience
Board Certifications
- Vascular Surgery
- General Surgery
Academic Title(s)
Professor, Surgery and RadiologyDivision of General Surgery
Vascular Surgery Section
Research Interests
Dr. Geraghty serves as national or local principal investigator for a number of clinical trials of endovascular intervention, including the VIBRANT trial (percutaneous treatment of leg artery blockages for claudication) and the VIVA-1: XCELL Trial (percutaneous treatment of leg artery blockages for crirical limb ischemia). He is also interested in the design, application, and outcomes of innovative, minimally invasive (endovascular) methods of treating leg artery blockages; the outcomes of endovascular repair of abdominal and thoracic aneurysms; and innovative methods to improve dialysis access.
Publications & Research
View research profile »Education
Washington University School of Medicine, St. Louis, MO
University of Michigan Hospitals, Ann Arbor MI
University of Michigan Hospitals, Ann Arbor, MI
Northwestern University School of Medicine, Chicago, IL
- Aveera
- Equity: Yes
- Reporting Date: 05/01/2023
- MedAlliance
- Equity: Yes
- Reporting Date: 05/01/2023
- Pulse Therapeutics
- Equity: Yes
- Reporting Date: 05/01/2023
Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.